ZYME – zymeworks inc. (US:NASDAQ)

News

Zymeworks Inc. (NYSE: ZYME) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Zymeworks Announces Participation in Upcoming Investor Conferences
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com